Soluble epoxide hydrolase: a novel target for the treatment of hypertension.

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Epoxide hydrolases are a group of enzymes that convert the epoxide group of chemical compounds to corresponding diols by the addition of water. Soluble epoxide hydrolase (sEH, formerly referred to as cytosolic epoxide hydrolase), which is widely distributed in mammalian tissues, is the primary enzyme responsible for the conversion of epoxyeicosatrienoic acids (EETs), the bioactive lipid mediators formed from arachidonic acid by cytochrome P450 epoxygenase, to their corresponding diols. EETs, but not their diols, are endogenous anti-hypertensive eicosanoids. Disruption of the sEH gene in male mice decreases blood pressure, and inhibition of sEH decreases blood pressure in several experimental hypertensive models. Potent selective sEH inhibitors have been developed, and these sEH inhibitors have potential to become a novel class of anti-hypertensive drug.

Original languageEnglish (US)
Pages (from-to)67-72
Number of pages6
JournalRecent Patents on Cardiovascular Drug Discovery
Volume1
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Epoxide Hydrolases
Hypertension
Antihypertensive Agents
Blood Pressure
Eicosanoids
Epoxy Compounds
Enzymes
Arachidonic Acid
Cytochrome P-450 Enzyme System
Theoretical Models
Lipids
Acids
Water
Genes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery

Cite this

Soluble epoxide hydrolase : a novel target for the treatment of hypertension. / Fang, Xiang.

In: Recent Patents on Cardiovascular Drug Discovery, Vol. 1, No. 1, 01.2006, p. 67-72.

Research output: Contribution to journalArticle

@article{6136cdba93ce4f8386828d15eebdb7f6,
title = "Soluble epoxide hydrolase: a novel target for the treatment of hypertension.",
abstract = "Epoxide hydrolases are a group of enzymes that convert the epoxide group of chemical compounds to corresponding diols by the addition of water. Soluble epoxide hydrolase (sEH, formerly referred to as cytosolic epoxide hydrolase), which is widely distributed in mammalian tissues, is the primary enzyme responsible for the conversion of epoxyeicosatrienoic acids (EETs), the bioactive lipid mediators formed from arachidonic acid by cytochrome P450 epoxygenase, to their corresponding diols. EETs, but not their diols, are endogenous anti-hypertensive eicosanoids. Disruption of the sEH gene in male mice decreases blood pressure, and inhibition of sEH decreases blood pressure in several experimental hypertensive models. Potent selective sEH inhibitors have been developed, and these sEH inhibitors have potential to become a novel class of anti-hypertensive drug.",
author = "Xiang Fang",
year = "2006",
month = "1",
doi = "10.2174/157489006775244227",
language = "English (US)",
volume = "1",
pages = "67--72",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Soluble epoxide hydrolase

T2 - a novel target for the treatment of hypertension.

AU - Fang, Xiang

PY - 2006/1

Y1 - 2006/1

N2 - Epoxide hydrolases are a group of enzymes that convert the epoxide group of chemical compounds to corresponding diols by the addition of water. Soluble epoxide hydrolase (sEH, formerly referred to as cytosolic epoxide hydrolase), which is widely distributed in mammalian tissues, is the primary enzyme responsible for the conversion of epoxyeicosatrienoic acids (EETs), the bioactive lipid mediators formed from arachidonic acid by cytochrome P450 epoxygenase, to their corresponding diols. EETs, but not their diols, are endogenous anti-hypertensive eicosanoids. Disruption of the sEH gene in male mice decreases blood pressure, and inhibition of sEH decreases blood pressure in several experimental hypertensive models. Potent selective sEH inhibitors have been developed, and these sEH inhibitors have potential to become a novel class of anti-hypertensive drug.

AB - Epoxide hydrolases are a group of enzymes that convert the epoxide group of chemical compounds to corresponding diols by the addition of water. Soluble epoxide hydrolase (sEH, formerly referred to as cytosolic epoxide hydrolase), which is widely distributed in mammalian tissues, is the primary enzyme responsible for the conversion of epoxyeicosatrienoic acids (EETs), the bioactive lipid mediators formed from arachidonic acid by cytochrome P450 epoxygenase, to their corresponding diols. EETs, but not their diols, are endogenous anti-hypertensive eicosanoids. Disruption of the sEH gene in male mice decreases blood pressure, and inhibition of sEH decreases blood pressure in several experimental hypertensive models. Potent selective sEH inhibitors have been developed, and these sEH inhibitors have potential to become a novel class of anti-hypertensive drug.

UR - http://www.scopus.com/inward/record.url?scp=39049098184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049098184&partnerID=8YFLogxK

U2 - 10.2174/157489006775244227

DO - 10.2174/157489006775244227

M3 - Article

C2 - 18221075

AN - SCOPUS:39049098184

VL - 1

SP - 67

EP - 72

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 1

ER -